Literature DB >> 17200556

Mutagenesis and expression of the scaffolding Aalpha and Abeta subunits of PP2A: assays for measuring defects in binding of cancer-related Aalpha and Abeta mutants to the regulatory B and catalytic C subunits.

Ralf Ruediger1, Jin Zhou, Gernot Walter.   

Abstract

Protein phosphatase 2A (PP2A) holoenzymes are composed of three subunits: one scaffolding A subunit, one regulatory B subunit, and one catalytic C subunit. The A subunit exists as two isoforms: Aalpha and Abeta. The C subunit also exists as two isoforms (Calpha and Cbeta) and B subunits fall into three families (B, B', and B") comprising over 15 members. The Aalpha and Abeta subunits consist of 15 nonidentical repeats, which are composed of two amphipathic alpha helices that are connected by a loop (intrarepeat loop). These loops are instrumental in binding regulatory B and catalytic C subunits. The genes encoding the Aalpha and Abeta subunits are relatively frequent targets for mutation in human cancer. The mutations often affect the intrarepeat loops and cause defects in the binding of specific B subunits or of B and C subunits. Here, we describe in vitro and in vivo binding assays for measuring these defects. Knowing which B subunits are affected in binding to the mutant A subunits sheds light on which holoenzymes might be involved in growth control and cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200556     DOI: 10.1385/1-59745-267-X:85

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.

Authors:  Caitlin M O'Connor; Sarah E Taylor; Kathryn M Miller; Lauren Hurst; Terrance J Haanen; Tahra K Suhan; Kaitlin P Zawacki; Fallon K Noto; Jonida Trako; Arathi Mohan; Jaya Sangodkar; Dmitriy Zamarin; Analisa DiFeo; Goutham Narla
Journal:  Cancer Res       Date:  2022-02-15       Impact factor: 13.312

Review 2.  PP2A-Mediated Anticancer Therapy.

Authors:  Weibo Chen; Zhongxia Wang; Chunping Jiang; Yitao Ding
Journal:  Gastroenterol Res Pract       Date:  2013-11-07       Impact factor: 2.260

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.